Compare Organon & Co. Common Stock (OGN) vs Prudential PLC (PUK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Organon & Co. Common Stock vs Prudential PLC — how do they compare? Organon & Co. Common Stock trades at $13.58 (market cap $3.62B), while Prudential PLC trades at $23.79 (market cap $29.00B). The key difference: Prudential PLC is far larger — about 8× Organon & Co. Common Stock's market cap, and Prudential PLC pays the higher dividend (2.33%). Which is the better fit depends on your goals — on Pluang, investors hold Organon & Co. Common Stock for 0 Days and Prudential PLC for 119 Days on average.
| OGN | PUK | |
|---|---|---|
Market Cap | $3.62B | $29.00B |
Volume | 2,892,999 | 1,133,946 |
Sector | Health | Financials |
52-Week High | $13.81 | $33.61 |
52-Week Low | $5.70 | $23.54 |
Typical Hold Time | 0 Days | 119 Days |
Enterprise Value | $11.04B | $28.54B |
Dividend Yield | 0.58% | 2.33% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Organon (OGN) trades at $13.77, showing no change in the latest session. The stock demonstrates strong profitability with 52.68% gross margins and 24.04% ROE, though recent quarterly earnings have missed expectations. Valuation appears reasonable with P/E of 17.65 and P/S of 0.59. The company shows positive cash flow trends with 2026 projections indicating $533M net cash flow. Recent FDA developments for MIUDELLA and VTAMA products highlight ongoing pipeline progress.
OGN presents a mixed outlook with solid fundamentals offset by earnings misses. The healthcare company's improving cash flow and product pipeline offer potential upside, but investor sentiment remains divided with analysts showing cautious optimism. Key risks include execution challenges and competitive pressures in the pharmaceutical sector.
Prudential Public Limited Company (PUK) trades at $23.81, down 0.25% on the day, with mixed technical signals showing bearish moving averages but oversold RSI readings. The company demonstrates strong fundamentals with $27.39B revenue in 2025, 12.27% net income margin, and attractive valuation metrics including an 8.38 P/E ratio. Recent earnings show two beats and two misses in the last four quarters, while analyst sentiment remains moderately positive with 50% buy ratings.
PUK presents a compelling value opportunity with strong profitability and growth in Asian markets, though near-term technical weakness and emerging market exit execution risks warrant caution. The stock's current valuation discount to peers and consistent dividend payments provide downside protection, while strategic refocusing on core markets could drive long-term shareholder value.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Organon & Co. Common Stock
Organon & Co. is a global healthcare company focused on women's health, biosimilars, and established brands, spun off from Merck & Co. in 2021. Its portfolio of more than 70 medicines includes contraception and fertility therapies, immunology and oncology biosimilars, and treatments in cardiovascular, respiratory, and dermatology, distributed in over 140 countries.
Read more on OGN →About Prudential PLC
Prudential is an Asia and Africa health and life insurance business and is focused on long-term savings. The business is increasingly focusing on digital offerings and creating strong brand equity and relationships with customers of its products through these.
Read more on PUK →
